| Trial ID: | L2156 |
| Source ID: | NCT00094991
|
| Associated Drug: |
Muraglitazar
|
| Title: |
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Muraglitazar
|
| Outcome Measures: |
Primary: The change from baseline in insulin medicated glucose disposal after 16 weeks of treatment with Muraglitazar |
|
| Sponsor/Collaborators: |
Sponsor: Bristol-Myers Squibb | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
42
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-05
|
| Completion Date: |
2006-05
|
| Results First Posted: |
|
| Last Update Posted: |
2010-09-14
|
| Locations: |
Local Institution, San Antonio, Texas, 78229-3900, United States|Local Institution, Pisa, Italy
|
| URL: |
https://clinicaltrials.gov/show/NCT00094991
|
